Literature DB >> 15122649

Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.

Sherif Y Saad1, Tawfeeg A O Najjar, Mouied Alashari.   

Abstract

The higher incidence of cardiotoxicity of doxorubicin (DOX)/paclitaxel (PTX) combination compared with DOX alone remains to be a major obstacle against effective chemotherapeutic treatment. We investigated the effect of sequence and time interval between administration of both drugs on the severity of cardiotoxicity of the combination. Male Wistar rats were divided into seven groups. DOX was administered intraperitoneally (i.p.) at a single dose of 5 mg x kg(-1) every other 2 days, 2 doses per week for a total cumulative dose of 20 mg x kg(-1). PTX was administered by an i.p. route at a dose of 20 mg x kg(-1) every other 2 days. Both drugs were injected either alone or sequentially in combination. In one case, DOX preceded PTX by 30 min and 24 h and in the other case, PTX preceded DOX by 30 min and 24 h. Cardiotoxicity was evaluated by both biochemical and histopathological examination, 48 h after the last DOX dose. DOX-induced cardiotoxicity was manifested by abnormal biochemical changes including marked increases in serum creatine phosphokinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), glutathione peroxidase (GSH-Px), and aspartate aminotransferase (AST) activity levels. Myocardial tissue from DOX-treated rats showed significant increases in malondialdehyde (MDA) production and total nitrate/nitrite (NOx) levels, parallel with depletion of "endogenous antioxidant reserve," including GSH contents and GSH-Px activity level. PTX treatment produced significant changes in the biochemical parameters measured by a lower magnitude than those changes produced by DOX alone. Combination of both drugs resulted in aggravation of DOX-induced cardiotoxicity regardless the sequence and time interval between administration of either drug. Administration of PTX 30 min and 24 h after DOX treatment showed exaggeration of combination-induced cardiotoxicity compared with the reverse sequence. This exacerbation was manifested by much more pronounced changes in serum and cardiac tissue parameters measured. Histopathological examination of ventricles of rat's heart revealed that DOX treatment produced myo-cytolysis and myocardial necrosis. Administration of PTX following DOX treatment showed extensive myocardial necrosis compared with those rats treated with either DOX alone or the reverse sequence of administration. Moreover, rats treated with PTX 24 h after DOX treatment showed exaggeration of the combination-induced cardiotoxicity. In conclusion, PTX might synergistically aggravate DOX-induced cardiotoxicity. The effect might be much more pronounced with those rats treated with PTX 24 h after DOX treatment. Copyright 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122649     DOI: 10.1002/jbt.20012

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  14 in total

1.  Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.

Authors:  Yang Liu; Chi Chen; Xiaoxiang Duan; Wenting Ma; Man Wang; Mengyi Tu; Ying Chen
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

2.  Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.

Authors:  Hua Zhong; Baohui Han; Irina L Tourkova; Anna Lokshin; Alan Rosenbloom; Michael R Shurin; Galina V Shurin
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  Aptamer-Based Microfluidic Electrochemical Biosensor for Monitoring Cell-Secreted Trace Cardiac Biomarkers.

Authors:  Su Ryon Shin; Yu Shrike Zhang; Duck-Jin Kim; Ahmad Manbohi; Huseyin Avci; Antonia Silvestri; Julio Aleman; Ning Hu; Tugba Kilic; Wendy Keung; Martina Righi; Pribpandao Assawes; Hani A Alhadrami; Ronald A Li; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  Anal Chem       Date:  2016-10-04       Impact factor: 6.986

4.  A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.

Authors:  Gian Piero Carboni
Journal:  Am J Cardiovasc Dis       Date:  2012-10-25

Review 5.  Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.

Authors:  Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva
Journal:  Front Cardiovasc Med       Date:  2022-04-15

6.  Cardioprotective effect of royal jelly on paclitaxel-induced cardio-toxicity in rats.

Authors:  Hassan Malekinejad; Sima Ahsan; Fatemeh Delkhosh-Kasmaie; Hadi Cheraghi; Ali Rezaei-Golmisheh; Hamed Janbaz-Acyabar
Journal:  Iran J Basic Med Sci       Date:  2016-02       Impact factor: 2.699

7.  Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death.

Authors:  Chih-Yang Huang; Wei-Wen Kuo; Jeng-Fan Lo; Tsung-Jung Ho; Pei-Ying Pai; Shu-Fen Chiang; Pei-Yu Chen; Fu-Jen Tsai; Chang-Hai Tsai; Chih-Yang Huang
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

8.  Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.

Authors:  Reem Ali Shaker; Samer Hassan Abboud; Hayder Chasib Assad; Najah Hadi
Journal:  BMC Pharmacol Toxicol       Date:  2018-01-10       Impact factor: 2.483

9.  Nuclear interaction between ADR-induced p65 and p53 mediates cardiac injury in iNOS (-/-) mice.

Authors:  Marsha P Cole; Jitbanjong Tangpong; Terry D Oberley; Luksana Chaiswing; Kinsley K Kiningham; Daret K St Clair
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

Review 10.  Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers.

Authors:  Monica Lamberti; Giancarlo Giovane; Elpidio M Garzillo; Franca Avino; Antonia Feola; Stefania Porto; Vincenzo Tombolini; Marina Di Domenico
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.